论文部分内容阅读
一个把分子生物学用于临床的新研究所上星期在牛津成立,投资为七百万英镑,作为牛津大学一部份的分子医学研究所可容纳大约10个相对独立的研究小组。研究所所长David Weatherall把该所比做“研究旅馆”,各研究小组将互相竞争,只有当他们的研究具有创造性和成功时,才能被聘用。 Weatherall相信这种研究所在英国仅此一家,它有助于纠正英国分子生物学在临床医学应用方面远远落后的缺陷,造成这种现象的原因部份是由于很难劝说搞基础的科学家放弃基础研究而去从事临床医学研究,医学院中几乎没有教研室能提供临床研究所必须的昂贵的设备和器材。
A new Institute for Molecular Biology in Clinics was founded last week in Oxford with an investment of £ 7 million. The Institute of Molecular Medicine, part of Oxford University, accommodates about 10 relatively independent research groups. David Weatherall, director of the institute, compared the institute to a “research hotel,” and research teams compete with one another and can only be hired when their research is creative and successful. Weatherall believes the institute, the only one in the UK that helps to correct the flaw in British molecular biology that lags far behind clinical applications, is partly due to the difficulty in persuading scientists to give up Basic research goes to engage in clinical research, medical school almost no teaching room can provide the necessary clinical research equipment and equipment.